Want to see CELC full AI Analyst Report?
CELC Stock Chart & Stats
$82.62
$0.23(0.28%)
At close: 4:00 PM EDT
$82.62
$0.23(0.28%)
Day’s Range― - ―
52-Week Range$34.30 - $151.02
Previous CloseN/A
Volume428.06K
Average Volume (3M)1.57M
Market Cap
$4.01B
Enterprise Value$6.15K
Total Cash (Recent Filing)$145.19M
Total Debt (Recent Filing)$195.58M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 06, 2026EPS Estimate
-1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding48,766,290
10 Day Avg. Volume2,363,349
30 Day Avg. Volume1,572,523
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$165.00Price Target Upside99.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.22
Revenue Forecast (FY)$39.92M
Bulls Say, Bears Say
Bulls Say
Regulatory Approval (commercial Milestone)FDA approval converts Celcuity from pre-commercial to a commercial-stage oncology company for a defined HR+/HER2- indication, enabling first product revenue, payer engagement, and commercialization scale-up. This materially reduces binary regulatory risk for the approved label and anchors near-term commercial execution.
Robust Phase III EfficacyClear superiority in Phase III provides a durable clinical differentiation versus existing PAM inhibitors, supporting physician adoption, payer coverage, and label expansion. Strong efficacy and tolerability underpin a sustainable competitive advantage and increase likelihood of broader market penetration over multiple lines.
Refinancing And Near-term Funding RunwayThe convertible notes and cash balance materially extend financing runway and lower near-term interest burdens, providing durable funding for launch, manufacturing scale-up and additional studies. Improved maturity profile reduces short-term refinancing risk and supports execution on commercialization and label-expansion plans.
Bears Say
Pre-revenue, Heavy Cash BurnSubstantial and growing cash burn while revenues are absent forces ongoing reliance on capital markets or debt to fund operations. That structural funding need elevates execution risk, can constrain long-term R&D/commercial investments if markets tighten, and pressures management to balance spend with access to funding.
Elevated Leverage And Dilution RiskA sharp step-up in leverage reduces financial flexibility and increases fixed obligations. Use of convertible securities mitigates cash interest but creates potential equity dilution on conversion, which can impair shareholder value and limit strategic optionality if commercial uptake is slower than forecast.
Long Regulatory And Development TimelinesKey expansions (first-line label, subcutaneous formulation) require multi-year studies and regulatory work, delaying broader market access and full peak-revenue realization. Extended timelines sustain high spend and expose commercialization plans to longer-term clinical, regulatory and payer uncertainties.
Celcuity News
CELC FAQ
What was Celcuity Inc.’s price range in the past 12 months?
Celcuity Inc. lowest stock price was $34.30 and its highest was $151.02 in the past 12 months.
What is Celcuity Inc.’s market cap?
Celcuity Inc.’s market cap is $4.01B.
When is Celcuity Inc.’s upcoming earnings report date?
Celcuity Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 8 days.
How were Celcuity Inc.’s earnings last quarter?
Celcuity Inc. released its earnings results on May 14, 2026. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $0.07.
Is Celcuity Inc. overvalued?
According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued.
Does Celcuity Inc. pay dividends?
Celcuity Inc. does not currently pay dividends.
What is Celcuity Inc.’s EPS estimate?
Celcuity Inc.’s EPS estimate is -1.17.
How many shares outstanding does Celcuity Inc. have?
Celcuity Inc. has 48,766,290 shares outstanding.
What happened to Celcuity Inc.’s price movement after its last earnings report?
Celcuity Inc. reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 2.197%.
Which hedge fund is a major shareholder of Celcuity Inc.?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.00 (99.71% Upside)
$165.00 (99.71% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $317.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 14.0%
Last 30 Days ▲ 14.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
488.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
88.04%
Trailing 12-Months
Company Description
Celcuity Inc.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
CELC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was clinically very positive: robust Phase III efficacy signals in both wild-type and mutant cohorts, expansion into first-line studies, promising prostate cancer combo data, IP and formulation work for a subcutaneous version, and a staffed commercial organization targeting a large (~$5B+) second-line market and potential peak revenues up to $2.5B. Offsetting these achievements are materially higher losses and cash burn (net loss up ≈43%, non-GAAP loss up ≈35%, operating cash use up ≈54%), a large increase in SG&A (≈176%), runway that extends through 2027 only with debt drawdowns, and regulatory/clinical timelines (notably first-line data by 2028–2030 and potential additional studies for subcutaneous formulation) that delay broader commercialization. On balance, strong clinical progress and commercial preparations outweigh the near-term financial and timing challenges, but the company will need to manage cash and regulatory requirements closely.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$165.00
▲(99.71% Upside)
Technical Analysis
Cidara Therapeutics
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
18.33% Insiders
12.24% Mutual Funds
1.18% Other Institutional Investors
57.23% Public Companies and Individual Investors